Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pharmala Biotech Holdings Inc MDXXF


Primary Symbol: C.MDMA

PharmAla Biotech Holdings Inc. is a Canada-based biotechnology company. The Company is focused on the development, manufacture and sales of methylenedioxy methamphetamine (MDMA) and methylenedioxy phenethylamines (MDXX) class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The Company has three primary business lines... see more

Recent & Breaking News (CSE:MDMA)

Canadian Investment Regulatory Organization Trading Halt - MDMA

Canada NewsWire March 20, 2024

Cortexa Leads the World in First Supply of Psilocybin Under the TGA's Authorized Prescriber Scheme

GlobeNewswire March 18, 2024

PharmAla Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update

GlobeNewswire March 8, 2024

Red Light Holland Commences Experimental Research on Psilocybin Truffles to Develop Process for Commercial Manufacturing of Natural-Source Active Pharmaceutical Ingredient

Newsfile March 8, 2024

PharmAla named an Intellectual Property Ontario Client

GlobeNewswire February 22, 2024

PharmAla Data to be Published in ACS Chemical Neuroscience

GlobeNewswire February 20, 2024

PharmAla and Red Light Holland to Collaborate on Medical Psilocybin Development

GlobeNewswire February 9, 2024

PharmAla releases Profitable Q1 Interim Financial Statement and Business Update

GlobeNewswire January 31, 2024

PharmAla approved to sell MDMA and psilocybin in Canada

Trevor Abes  January 26, 2024

Canadian Investment Regulatory Organization Trade Resumption - MDMA

Canada NewsWire January 25, 2024

PharmAla granted a Controlled Drugs & Substances Dealer's License by Health Canada

GlobeNewswire January 25, 2024

Canadian Investment Regulatory Organization Trading Halt - MDMA

Canada NewsWire January 25, 2024

PharmAla receives new "MDXXF" ticker from FINRA for OTCQB Listing

GlobeNewswire January 24, 2024

PharmAla Biotech gets U.S. patent prosecution highway acceptance

Jocelyn Aspa January 8, 2024

PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance

GlobeNewswire January 8, 2024

PharmAla Files Audited Financials for Year Ending August 31, 2023

GlobeNewswire December 29, 2023

PharmAla Biotech and Filament Health Announce Release of Second Batch of GMP MDMA Capsules

GlobeNewswire November 15, 2023

First trial to assess real-world efficacy of MDMA in treating PTSD

Jonathon Brown November 9, 2023

World's First Observational Trial to Assess Real-World Efficacy of MDMA Treatment

GlobeNewswire November 9, 2023

PharmAla Partners with Clariti Strategic Advisors(TM)

GlobeNewswire November 8, 2023